Fuse develops and manufactures innovative diagnostic products for a range of industries delivering lab quality information wherever it is needed through ultra-rapid, low-cost tests.

The immunoassay and PCR technologies that dominate the diagnostics industry have consistently failed to deliver lab-quality tests that are suitable for widespread decentralised use.  Using an all-new multianalytic chemistry and breakthrough product innovations Fuse has overcome the cost and performance challenges of established approaches to make accurate, point-of-need testing a reality for all.

Fuse Diagnostics

Following hot on the heels of our £1.6m seed round we are pleased to further announce a $1m Carb-X backed programme using our technology platforms to develop a CT/NG test to help in the fight against antimicrobial resistance. 💥 🎉 

https://fuse-dx.com/news

CARB-X will award US$1 million to Fuse Diagnostics to demonstrate proof-of-concept and feasibility ahead of the development of a rapid, instrument-free diagnostic for the detection of Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG). 
 
Gonorrhea, caused by Neisseria gonorrhoeae, is the second-most reported bacterial sexually transmitted infection, infecting approximately 82 million people globally in 2020. Patients with gonorrhea may experience serious health effects, including pelvic inflammatory disease, chronic pain, and infertility. Untreated gonorrhea can spread to the blood stream, which can be life threatening, and increase the risk of HIV infection. 
 
The award will fund the demonstration of performance of Fuse's CT/NG test, Apex, on clinical samples. Apex CT/NG utilizes innovative device designs and molecular technologies with the potential to deliver accuracy that is equivalent to lab-based PCR systems in an ultra-rapid, low-cost format ideally suited to flexible global deployment, including areas with remote access to secondary healthcare in low- and middle-income countries (LMICs). 
 
🔗 Read more: bit.ly/3VmwmXp 

#AMR #StopSuperBugs #SuperBugs #AntibioticResistance #Medicine #GlobalHealth #Innovation #Biotechnology #LMICs #antibiotics 

Boston University School of Law Boston University Biomedical Advanced Research and Development Authority (BARDA) HHS Administration for Strategic Preparedness and Response National Institute of Allergy and Infectious Diseases (NIAID) Wellcome Trust Bundesministerium für Bildung und Forschung Bill & Melinda Gates Foundation Government of Canada Novo Nordisk Foundation Centre for Cellular and Molecular Platforms (C-CAMP) FIND German Center for Infection Research Institute For Life Science Entrepreneurship (ILSE)

Lucira Pfizer is a company focused on developing and commercializing infectious disease testing solutions, including molecular diagnostics.

Lucira Pfizer

Fluxergy is a company specializing in the development of rapid molecular diagnostic testing platforms for various applications.

Fluxergy

My110 is a company that focuses on developing innovative diagnostic tests for various medical applications, including molecular diagnostics.

My110

Luas Diagnostics is a company specializing in the development of advanced molecular diagnostic solutions for healthcare applications.

Luas Diagnostics

Oxsed is a company focused on the development of rapid and accurate diagnostic solutions, including molecular diagnostics, for infectious diseases.

Oxsed

DxLab is a company specializing in the development of molecular diagnostic testing platforms and solutions for various medical applications.

DxLab

BioHermes is a company that focuses on the development and commercialization of molecular diagnostic tools and solutions for healthcare applications.

BioHermes

VIRIS Detection Systems is a company specializing in the development of advanced molecular diagnostic systems for the detection of infectious diseases.

VIRIS Detection Systems

Fuse Diagnostics is a company specializing in the development of innovative, rapid, low-cost diagnostic tests that bridge the gap between laboratory-based and point-of-need testing.

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general	Jul 4, 2024 10:48 PM	723760f2
public peers	general	Jul 3, 2024 10:09 PM	37f4b31f
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Jul 3, 2024 10:14 PM	275d254d
company summary	general
signals	general
crunchbase trigger	general	Oct 31, 2024 9:55 AM	e6e5144a
crunchbase profile	general
li profile	general	Jul 3, 2024 10:09 PM	3c740f6c
translate crunchbase fundingrounds	general
peers	general	Jul 3, 2024 10:09 PM	205779d2
news basic	general	Jul 3, 2024 10:09 PM	883ee53c
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:FUSE-DX

Fuse Diagnostics